Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Interactive visual analysis of drug-target interaction networks using Drug Target Profiler, with applications to precision medicine and drug repurposing.

Tanoli Z, Alam Z, Ianevski A, Wennerberg K, Vähä-Koskela M, Aittokallio T.

Brief Bioinform. 2018 Dec 18. doi: 10.1093/bib/bby119. [Epub ahead of print]

PMID:
30566623
2.

Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles.

Tanoli Z, Alam Z, Vähä-Koskela M, Ravikumar B, Malyutina A, Jaiswal A, Tang J, Wennerberg K, Aittokallio T.

Database (Oxford). 2018 Jan 1;2018:1-13. doi: 10.1093/database/bay083.

3.

PROX1 is a transcriptional regulator of MMP14.

Gramolelli S, Cheng J, Martinez-Corral I, Vähä-Koskela M, Elbasani E, Kaivanto E, Rantanen V, Tuohinto K, Hautaniemi S, Bower M, Haglund C, Alitalo K, Mäkinen T, Petrova TV, Lehti K, Ojala PM.

Sci Rep. 2018 Jun 22;8(1):9531. doi: 10.1038/s41598-018-27739-w.

4.

Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions.

Tang J, Tanoli ZU, Ravikumar B, Alam Z, Rebane A, Vähä-Koskela M, Peddinti G, van Adrichem AJ, Wakkinen J, Jaiswal A, Karjalainen E, Gautam P, He L, Parri E, Khan S, Gupta A, Ali M, Yetukuri L, Gustavsson AL, Seashore-Ludlow B, Hersey A, Leach AR, Overington JP, Repasky G, Wennerberg K, Aittokallio T.

Cell Chem Biol. 2018 Feb 15;25(2):224-229.e2. doi: 10.1016/j.chembiol.2017.11.009. Epub 2017 Dec 21.

5.

Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins.

Bulanova D, Ianevski A, Bugai A, Akimov Y, Kuivanen S, Paavilainen H, Kakkola L, Nandania J, Turunen L, Ohman T, Ala-Hongisto H, Pesonen HM, Kuisma MS, Honkimaa A, Walton EL, Oksenych V, Lorey MB, Guschin D, Shim J, Kim J, Than TT, Chang SY, Hukkanen V, Kulesskiy E, Marjomaki VS, Julkunen I, Nyman TA, Matikainen S, Saarela JS, Sane F, Hober D, Gabriel G, De Brabander JK, Martikainen M, Windisch MP, Min JY, Bruzzone R, Aittokallio T, Vähä-Koskela M, Vapalahti O, Pulk A, Velagapudi V, Kainov DE.

Viruses. 2017 Sep 25;9(10). pii: E271. doi: 10.3390/v9100271.

6.

Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas.

Niittykoski M, von Und Zu Fraunberg M, Martikainen M, Rauramaa T, Immonen A, Koponen S, Leinonen V, Vähä-Koskela M, Zhang Q, Kühnel F, Mei YF, Ylä-Herttuala S, Jääskeläinen JE, Hinkkanen A.

Transl Oncol. 2017 Oct;10(5):772-779. doi: 10.1016/j.tranon.2017.07.002. Epub 2017 Aug 4.

7.

Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System.

Cerullo V, Capasso C, Vaha-Koskela M, Hemminki O, Hemminki A.

Curr Cancer Drug Targets. 2018;18(2):124-138. doi: 10.2174/1568009617666170502152352. Review.

PMID:
28464762
8.

Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.

Hekim C, Ilander M, Yan J, Michaud E, Smykla R, Vähä-Koskela M, Savola P, Tähtinen S, Saikko L, Hemminki A, Kovanen PE, Porkka K, Lee FY, Mustjoki S.

Cancer Immunol Res. 2017 Feb;5(2):157-169. doi: 10.1158/2326-6066.CIR-16-0061-T. Epub 2017 Jan 10.

9.

Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma".

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther. 2016 Nov;24(11):2033. doi: 10.1038/mt.2016.196. No abstract available.

10.

T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.

Tähtinen S, Blattner C, Vähä-Koskela M, Saha D, Siurala M, Parviainen S, Utikal J, Kanerva A, Umansky V, Hemminki A.

J Immunother. 2016 Nov/Dec;39(9):343-354.

PMID:
27741089
11.

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity.

Hirvinen M, Capasso C, Guse K, Garofalo M, Vitale A, Ahonen M, Kuryk L, Vähä-Koskela M, Hemminki A, Fortino V, Greco D, Cerullo V.

Mol Ther Oncolytics. 2016 Mar 23;3:16002. doi: 10.1038/mto.2016.2. eCollection 2016.

12.

Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.

Siurala M, Vähä-Koskela M, Havunen R, Tähtinen S, Bramante S, Parviainen S, Mathis JM, Kanerva A, Hemminki A.

Oncoimmunology. 2016 Feb 18;5(5):e1136046. doi: 10.1080/2162402X.2015.1136046. eCollection 2016 May.

13.

Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther. 2016 Aug;24(8):1435-43. doi: 10.1038/mt.2016.137. Epub 2016 Jun 30. Erratum in: Mol Ther. 2016 Nov;24(11):2033.

14.

Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

Taipale K, Liikanen I, Juhila J, Turkki R, Tähtinen S, Kankainen M, Vassilev L, Ristimäki A, Koski A, Kanerva A, Diaconu I, Cerullo V, Vähä-Koskela M, Oksanen M, Linder N, Joensuu T, Lundin J, Hemminki A.

Mol Ther. 2016 Feb;24(1):175-83. doi: 10.1038/mt.2015.143. Epub 2015 Aug 27.

15.

MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.

Martikainen M, Niittykoski M, von und zu Fraunberg M, Immonen A, Koponen S, van Geenen M, Vähä-Koskela M, Ylösmäki E, Jääskeläinen JE, Saksela K, Hinkkanen A.

J Virol. 2015 Oct;89(20):10637-47. doi: 10.1128/JVI.01868-15. Epub 2015 Aug 12.

16.

Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles.

Autio KP, Ruotsalainen JJ, Anttila MO, Niittykoski M, Waris M, Hemminki A, Vähä-Koskela MJ, Hinkkanen AE.

BMC Vet Res. 2015 Jul 28;11:170. doi: 10.1186/s12917-015-0498-2.

17.

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.

Tähtinen S, Kaikkonen S, Merisalo-Soikkeli M, Grönberg-Vähä-Koskela S, Kanerva A, Parviainen S, Vähä-Koskela M, Hemminki A.

PLoS One. 2015 Jun 24;10(6):e0131242. doi: 10.1371/journal.pone.0131242. eCollection 2015.

18.

Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.

Tähtinen S, Grönberg-Vähä-Koskela S, Lumen D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, Vähä-Koskela M, Hemminki A.

Cancer Immunol Res. 2015 Aug;3(8):915-25. doi: 10.1158/2326-6066.CIR-14-0220-T. Epub 2015 May 14.

19.

Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.

Bramante S, Kaufmann JK, Veckman V, Liikanen I, Nettelbeck DM, Hemminki O, Vassilev L, Cerullo V, Oksanen M, Heiskanen R, Joensuu T, Kanerva A, Pesonen S, Matikainen S, Vähä-Koskela M, Koski A, Hemminki A.

Int J Cancer. 2015 Oct 1;137(7):1775-83. doi: 10.1002/ijc.29536. Epub 2015 Apr 11.

20.

Incomplete but infectious vaccinia virions are produced in the absence of oncolysis in feline SCCF1 cells.

Parviainen S, Autio K, Vähä-Koskela M, Guse K, Pesonen S, Rosol TJ, Zhao F, Hemminki A.

PLoS One. 2015 Mar 23;10(3):e0120496. doi: 10.1371/journal.pone.0120496. eCollection 2015.

21.

T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.

Taipale K, Liikanen I, Juhila J, Karioja-Kallio A, Oksanen M, Turkki R, Linder N, Lundin J, Ristimäki A, Kanerva A, Koski A, Joensuu T, Vähä-Koskela M, Hemminki A.

Mol Ther. 2015 May;23(5):964-973. doi: 10.1038/mt.2015.17. Epub 2015 Feb 6. Erratum in: Mol Ther. 2016 Jun;24(6):1159.

22.

Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.

Vähä-Koskela M, Tähtinen S, Grönberg-Vähä-Koskela S, Taipale K, Saha D, Merisalo-Soikkeli M, Ahonen M, Rouvinen-Lagerström N, Hirvinen M, Veckman V, Matikainen S, Zhao F, Pakarinen P, Salo J, Kanerva A, Cerullo V, Hemminki A.

Mol Ther Oncolytics. 2015 Jan 7;1:14006. doi: 10.1038/mto.2014.6. eCollection 2015.

23.

Anti-tumour activity of oncolytic Western Reserve vaccinia viruses in canine tumour cell lines, xenografts, and fresh tumour biopsies.

Autio K, Knuuttila A, Kipar A, Ahonen M, Parviainen S, Diaconu I, Kanerva A, Hakonen T, Vähä-Koskela M, Hemminki A.

Vet Comp Oncol. 2016 Dec;14(4):395-408. doi: 10.1111/vco.12119. Epub 2014 Oct 10.

PMID:
25302859
24.

Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.

Ruotsalainen JJ, Kaikkonen MU, Niittykoski M, Martikainen MW, Lemay CG, Cox J, De Silva NS, Kus A, Falls TJ, Diallo JS, Le Boeuf F, Bell JC, Ylä-Herttuala S, Hinkkanen AE, Vähä-Koskela MJ.

Gene Ther. 2015 Jan;22(1):65-75. doi: 10.1038/gt.2014.83. Epub 2014 Sep 18.

PMID:
25231172
25.

GMCSF-armed vaccinia virus induces an antitumor immune response.

Parviainen S, Ahonen M, Diaconu I, Kipar A, Siurala M, Vähä-Koskela M, Kanerva A, Cerullo V, Hemminki A.

Int J Cancer. 2015 Mar 1;136(5):1065-72. doi: 10.1002/ijc.29068. Epub 2014 Jul 10.

26.

Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.

Siurala M, Bramante S, Vassilev L, Hirvinen M, Parviainen S, Tähtinen S, Guse K, Cerullo V, Kanerva A, Kipar A, Vähä-Koskela M, Hemminki A.

Int J Cancer. 2015 Feb 15;136(4):945-54. doi: 10.1002/ijc.29048. Epub 2014 Jul 3.

27.

Tumor Restrictions to Oncolytic Virus.

Vähä-Koskela M, Hinkkanen A.

Biomedicines. 2014 Apr 17;2(2):163-194. doi: 10.3390/biomedicines2020163. Review.

28.

Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles.

Autio K, Knuuttila A, Kipar A, Pesonen S, Guse K, Parviainen S, Rajamäki M, Laitinen-Vapaavuori O, Vähä-Koskela M, Kanerva A, Hemminki A.

Mol Ther Oncolytics. 2014 Dec 10;1:14002. doi: 10.1038/mto.2014.2. eCollection 2014.

29.

CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.

Parviainen S, Ahonen M, Diaconu I, Hirvinen M, Karttunen Å, Vähä-Koskela M, Hemminki A, Cerullo V.

Gene Ther. 2014 Feb;21(2):195-204. doi: 10.1038/gt.2013.73. Epub 2013 Dec 5.

PMID:
24305418
30.

In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders.

Hemminki O, Immonen R, Närväinen J, Kipar A, Paasonen J, Jokivarsi KT, Yli-Ollila H, Soininen P, Partanen K, Joensuu T, Parvianen S, Pesonen SK, Koski A, Vähä-Koskela M, Cerullo V, Pesonen S, Gröhn OH, Hemminki A.

Int J Cancer. 2014 Jun 15;134(12):2878-90. doi: 10.1002/ijc.28615. Epub 2013 Dec 6.

31.

Model-based rational design of an oncolytic virus with improved therapeutic potential.

Le Bœuf F, Batenchuk C, Vähä-Koskela M, Breton S, Roy D, Lemay C, Cox J, Abdelbary H, Falls T, Waghray G, Atkins H, Stojdl D, Diallo JS, Kærn M, Bell JC.

Nat Commun. 2013;4:1974. doi: 10.1038/ncomms2974.

PMID:
23764612
32.

MicroRNA-mediated suppression of oncolytic adenovirus replication in human liver.

Ylösmäki E, Lavilla-Alonso S, Jäämaa S, Vähä-Koskela M, af Hällström T, Hemminki A, Arola J, Mäkisalo H, Saksela K.

PLoS One. 2013;8(1):e54506. doi: 10.1371/journal.pone.0054506. Epub 2013 Jan 22.

33.

Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma.

Vähä-Koskela MJ, Le Boeuf F, Lemay C, De Silva N, Diallo JS, Cox J, Becker M, Choi Y, Ananth A, Sellers C, Breton S, Roy D, Falls T, Brun J, Hemminki A, Hinkkanen A, Bell JC.

J Virol. 2013 Feb;87(4):2363-6. doi: 10.1128/JVI.01609-12. Epub 2012 Dec 5.

34.

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy.

Cerullo V, Vähä-Koskela M, Hemminki A.

Oncoimmunology. 2012 Sep 1;1(6):979-981.

35.

Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.

Cerullo V, Koski A, Vähä-Koskela M, Hemminki A.

Adv Cancer Res. 2012;115:265-318. doi: 10.1016/B978-0-12-398342-8.00008-2. Review.

PMID:
23021247
36.

Interferon-β sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models.

Ruotsalainen J, Martikainen M, Niittykoski M, Huhtala T, Aaltonen T, Heikkilä J, Bell J, Vähä-Koskela M, Hinkkanen A.

Mol Ther. 2012 Aug;20(8):1529-39. doi: 10.1038/mt.2012.53. Epub 2012 Mar 20.

37.

Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains.

Diallo JS, Vähä-Koskela M, Le Boeuf F, Bell J.

Methods Mol Biol. 2012;797:127-40. doi: 10.1007/978-1-61779-340-0_10.

PMID:
21948474
38.

A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizers.

Diallo JS, Le Boeuf F, Lai F, Cox J, Vaha-Koskela M, Abdelbary H, MacTavish H, Waite K, Falls T, Wang J, Brown R, Blanchard JE, Brown ED, Kirn DH, Hiscott J, Atkins H, Lichty BD, Bell JC.

Mol Ther. 2010 Jun;18(6):1123-9. doi: 10.1038/mt.2010.67. Epub 2010 Apr 13.

39.

Novel oncolytic viruses: riding high on the next wave?

Stanford MM, Bell JC, Vähä-Koskela MJ.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):177-83. doi: 10.1016/j.cytogfr.2010.02.012. Epub 2010 Mar 12. Review.

PMID:
20219409
40.

Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.

Evgin L, Vähä-Koskela M, Rintoul J, Falls T, Le Boeuf F, Barrett JW, Bell JC, Stanford MM.

Mol Ther. 2010 May;18(5):896-902. doi: 10.1038/mt.2010.14. Epub 2010 Feb 16.

41.

Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice.

Heikkilä JE, Vähä-Koskela MJ, Ruotsalainen JJ, Martikainen MW, Stanford MM, McCart JA, Bell JC, Hinkkanen AE.

PLoS One. 2010 Jan 6;5(1):e8603. doi: 10.1371/journal.pone.0008603.

42.

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Nguyên TL, Abdelbary H, Arguello M, Breitbach C, Leveille S, Diallo JS, Yasmeen A, Bismar TA, Kirn D, Falls T, Snoulten VE, Vanderhyden BC, Werier J, Atkins H, Vähä-Koskela MJ, Stojdl DF, Bell JC, Hiscott J.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14981-6. doi: 10.1073/pnas.0803988105. Epub 2008 Sep 24.

43.

Replication competent Semliki Forest virus prolongs survival in experimental lung cancer.

Määttä AM, Mäkinen K, Ketola A, Liimatainen T, Yongabi FN, Vähä-Koskela M, Pirinen R, Rautsi O, Pellinen R, Hinkkanen A, Wahlfors J.

Int J Cancer. 2008 Oct 1;123(7):1704-11. doi: 10.1002/ijc.23646.

44.

Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.

Määttä AM, Liimatainen T, Wahlfors T, Wirth T, Vähä-Koskela M, Jansson L, Valonen P, Häkkinen K, Rautsi O, Pellinen R, Mäkinen K, Hakumäki J, Hinkkanen A, Wahlfors J.

Int J Cancer. 2007 Aug 15;121(4):863-70.

45.

Oncolytic viruses in cancer therapy.

Vähä-Koskela MJ, Heikkilä JE, Hinkkanen AE.

Cancer Lett. 2007 Sep 8;254(2):178-216. Epub 2007 Mar 23. Review.

PMID:
17383089
46.

Semliki Forest virus vectors expressing transforming growth factor beta inhibit experimental autoimmune encephalomyelitis in Balb/c mice.

Vähä-Koskela MJ, Kuusinen TI, Holmlund-Hampf JC, Furu PT, Heikkilä JE, Hinkkanen AE.

Biochem Biophys Res Commun. 2007 Apr 13;355(3):776-81. Epub 2007 Feb 14.

PMID:
17316567
47.

Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.

Vähä-Koskela MJ, Kallio JP, Jansson LC, Heikkilä JE, Zakhartchenko VA, Kallajoki MA, Kähäri VM, Hinkkanen AE.

Cancer Res. 2006 Jul 15;66(14):7185-94.

48.

Semliki Forest virus A7(74) transduces hippocampal neurons and glial cells in a temperature-dependent dual manner.

Ehrengruber MU, Renggli M, Raineteau O, Hennou S, Vähä-Koskela MJ, Hinkkanen AE, Lundstrom K.

J Neurovirol. 2003 Feb;9(1):16-28.

PMID:
12587065
49.

A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus.

Vähä-Koskela MJ, Tuittila MT, Nygårdas PT, Nyman JK, Ehrengruber MU, Renggli M, Hinkkanen AE.

J Neurovirol. 2003 Feb;9(1):1-15.

PMID:
12587064

Supplemental Content

Loading ...
Support Center